Jeanette K Birnbaum1, Catherine Duggan1, Benjamin O Anderson2, Ruth Etzioni3. 1. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 2. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Surgery, University of Washington, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA. 3. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Statistics, University of Washington, Seattle, WA, USA. Electronic address: retzioni@fredhutch.org.
Abstract
BACKGROUND: Poor breast cancer survival in low-income and middle-income countries (LMICs) can be attributed to advanced-stage presentation and poor access to systemic therapy. We aimed to estimate the outcomes of different early detection strategies in combination with systemic chemotherapy and endocrine therapy in LMICs. METHODS: We adapted a microsimulation model to project outcomes of three early detection strategies alone or in combination with three systemic treatment programmes beyond standard of care (programme A): programme B was endocrine therapy for all oestrogen-receptor (ER)-positive cases; programme C was programme B plus chemotherapy for ER-negative cases; programme D was programme C plus chemotherapy for advanced ER-positive cases. The main outcomes were reductions in breast cancer-related mortality and lives saved per 100 000 women relative to the standard of care for women aged 30-49 years in a low-income setting (East Africa; using incidence data and life tables from Uganda and data on tumour characteristics from various East African countries) and for women aged 50-69 years in a middle-income setting (Colombia). FINDINGS: In the East African setting, relative mortality reductions were 8-41%, corresponding to 23 (95% uncertainty interval -12 to 49) to 114 (80 to 138) lives saved per 100 000 women over 10 years. In Colombia, mortality reductions were 7-25%, corresponding to 32 (-29 to 70) to 105 (61 to 141) lives saved per 100 000 women over 10 years. INTERPRETATION: The best projected outcomes were in settings where access to both early detection and adjuvant therapy is improved. Even in the absence of mammographic screening, improvements in detection can provide substantial benefit in settings where advanced-stage presentation is common. FUNDING: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Cancer Center Support Grant of the US National Institutes of Health.
BACKGROUND: Poor breast cancer survival in low-income and middle-income countries (LMICs) can be attributed to advanced-stage presentation and poor access to systemic therapy. We aimed to estimate the outcomes of different early detection strategies in combination with systemic chemotherapy and endocrine therapy in LMICs. METHODS: We adapted a microsimulation model to project outcomes of three early detection strategies alone or in combination with three systemic treatment programmes beyond standard of care (programme A): programme B was endocrine therapy for all oestrogen-receptor (ER)-positive cases; programme C was programme B plus chemotherapy for ER-negative cases; programme D was programme C plus chemotherapy for advanced ER-positive cases. The main outcomes were reductions in breast cancer-related mortality and lives saved per 100 000 women relative to the standard of care for women aged 30-49 years in a low-income setting (East Africa; using incidence data and life tables from Uganda and data on tumour characteristics from various East African countries) and for women aged 50-69 years in a middle-income setting (Colombia). FINDINGS: In the East African setting, relative mortality reductions were 8-41%, corresponding to 23 (95% uncertainty interval -12 to 49) to 114 (80 to 138) lives saved per 100 000 women over 10 years. In Colombia, mortality reductions were 7-25%, corresponding to 32 (-29 to 70) to 105 (61 to 141) lives saved per 100 000 women over 10 years. INTERPRETATION: The best projected outcomes were in settings where access to both early detection and adjuvant therapy is improved. Even in the absence of mammographic screening, improvements in detection can provide substantial benefit in settings where advanced-stage presentation is common. FUNDING: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Cancer Center Support Grant of the US National Institutes of Health.
Authors: Roman Shyyan; Stephen F Sener; Benjamin O Anderson; Leticia M Fernández Garrote; Gabriel N Hortobágyi; Julio A Ibarra; Britt-Marie Ljung; Hélène Sancho-Garnier; Helge Stalsberg Journal: Cancer Date: 2008-10-15 Impact factor: 6.860
Authors: Michel P Coleman; Manuela Quaresma; Franco Berrino; Jean-Michel Lutz; Roberta De Angelis; Riccardo Capocaccia; Paolo Baili; Bernard Rachet; Gemma Gatta; Timo Hakulinen; Andrea Micheli; Milena Sant; Hannah K Weir; J Mark Elwood; Hideaki Tsukuma; Sergio Koifman; Gulnar Azevedo E Silva; Silvia Francisci; Mariano Santaquilani; Arduino Verdecchia; Hans H Storm; John L Young Journal: Lancet Oncol Date: 2008-07-17 Impact factor: 41.316
Authors: E J Kantelhardt; P Zerche; A Mathewos; P Trocchi; A Addissie; A Aynalem; T Wondemagegnehu; T Ersumo; A Reeler; B Yonas; M Tinsae; T Gemechu; A Jemal; C Thomssen; A Stang; S Bogale Journal: Int J Cancer Date: 2014-01-10 Impact factor: 7.396
Authors: Catherine Duggan; Allison Dvaladze; Anne F Rositch; Ophira Ginsburg; Cheng-Har Yip; Susan Horton; Rolando Camacho Rodriguez; Alexandru Eniu; Miriam Mutebi; Jean-Marc Bourque; Shahla Masood; Karla Unger-Saldaña; Anna Cabanes; Robert W Carlson; Julie R Gralow; Benjamin O Anderson Journal: Cancer Date: 2020-05-15 Impact factor: 6.860
Authors: Paddy Ssentongo; John S Oh; Forster Amponsah-Manu; William Wong; Xavier Candela; Yubraj Acharya; Anna E Ssentongo; Daleela G Dodge Journal: Front Public Health Date: 2022-06-02
Authors: Zachary J Ward; Andrew M Scott; Hedvig Hricak; May Abdel-Wahab; Diana Paez; Miriam Mikhail Lette; H Alberto Vargas; T Peter Kingham; Rifat Atun Journal: Lancet Oncol Date: 2020-08 Impact factor: 41.316
Authors: Anna J Dare; Gregory C Knapp; Anya Romanoff; Olalekan Olasehinde; Olusola C Famurewa; Akinwumi O Komolafe; Samuel Olatoke; Aba Katung; Olusegun I Alatise; T Peter Kingham Journal: Cancer Prev Res (Phila) Date: 2021-09-10
Authors: Rupali Sood; Anne F Rositch; Delaram Shakoor; Emily Ambinder; Kara-Lee Pool; Erica Pollack; Daniel J Mollura; Lisa A Mullen; Susan C Harvey Journal: J Glob Oncol Date: 2019-08